glp 1 release date Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment GLP-1 Pipeline Update: February 2026

12.2 Pharmacodynamics Semaglutide lowers fasting and postprandial blood glucose and reduces body weight

A diagnosis of obesity (BMI 30), metabolic syndrome, or weight-related cardiovascular risk factors strengthens the medical necessity claim

For example, for dyspepsia, 40 mg of Astaxanthin by mouth daily in divided doses for four weeks

Serious but rare adverse effects: Whilst uncommon, several serious adverse effects require awareness

Whole-body care Beyond medication, we integrate nutrition, movement, sleep, and behavioral support through our proven Points Programso your care plan reflects you, not just your prescription